#1Teleflex Investor Presentation Teleflex®#22 Forward Looking Statements This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, including those risks and uncertainties discussed in our SEC filings, including our most recent Annual Report on Form 10-K. The forward-looking statements included in this presentation should not be unduly relied upon. These statements speak only as of the date made. Other than as required by applicable law, we do not intend, and do not assume any obligation, to update these forward-looking statements. This presentation reflects continuing operations. Teleflex®#3Our Core Values • Entrepreneurial Spirit Be creative, take risks, and show initiative Make it Fun • Initiate change and innovation • Take ownership and be accountable Build Trust • • Be sincere and authentic • Inform, ask, and listen Be supportive and reliable Entrepreneurials People 111 Building Trust 3 Make It Fun • . • Be collaborative and friendly Show appreciation Make your work place a better place People • People at the center of all we do • People drive innovation and success • People make us who we are Teleflex®#4Teleflex Today Our Purpose We are a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our Reach • • • ~14,000 employees¹ globally Global HQ: Wayne, PA, USA International HQ: Athlone, Ireland Serving healthcare providers worldwide through a combination of our direct sales force and distributors . NYSE listed - TFX • 2020 revenue of $2.537 billion Our Portfolio positions with established global brands ARROW DEKNATEL HUDSON RCI LMA Pilling • Leading market RUSCH 1Source: 2020 10-K filing Hospital & Healthcare Providers■ Medical Device Manufacturers Home Care 9% 3% 0 88% UROLIFT WECK Teleflex®#5Making a Difference Teleflex products are used everyday: 31,000 In 31,000 surgical procedures in the United States 6,000 To care for more than 6,000 patients globally in the Intensive Care Unit 1,600 To help more than 1,600 patients who require vascular access intervention globally 3,200 By emergency responders to treat 3,200 patients in the field globally Statistics included in the graphic above were calculated based on 2016 sales data, and management assumptions and estimates 5 Teleflex®#600 6 Demographics and Industry Tailwinds. 84M People 65+ years old in U.S. to double by 2050 versus 20121 1B+ People 50+ in Asia by 20252 Lower acuity patients moving to lower cost sites of service 1. U.S. Census Bureau: https://www.census.gov/library/publications/2014/demo/p25-1140.html https://www.census.gov/library/publications/2014/demo/p25-1141.html 2. APACMed: https://apacmed.org/content/uploads/2019/04/APACMed-Annual-Report-2019 Digital.pdf Teleflex®#77 Teleflex Investment Thesis Global Leadership Unique Size Track Record of Execution • . • Leading positions in growing markets (vascular, interventional access, interventional urology) Established and respected global brands Global scale to succeed in today's healthcare marketplace More nimble than larger device companies Constant currency revenue growth accelerated to 8.1% in FY19; declined 2.4% in 2020 due to COVID-19 490 basis point adjusted gross margin expansion from 2014 – 2020 520 basis point adjusted operating margin expansion from 2014-2020 Adjusted earnings per share CAGR of 10.9% from 2014-2020 Note: See appendicies for reconciliations of non-GAAP financial measures to the most comparable GAAP financial measures. Teleflex®#88 Leveraging Our Global Infrastructure Strategies • Realize margin expansion through ongoing restructuring initiatives • Leverage recent go-directs to strengthen control of commercial channels in Europe and Asia Drive adoption of high margin products in new markets ORANGE: Americas BLUE: Europe, Middle East and Africa GREEN: Asia Pacific Teleflex®#9Segment Revenue Review Dollars in Millions FY'20 Revenue FY'19 As- Reported Constant Currency Currency Revenue Revenue Impact Growth Growth Americas $1,465.0 $1,492.3 (1.8)% (0.2)% (1.6)% EMEA $584.9 $588.1 (0.5)% 1.1% (1.6)% Asia $267.0 $294.3 (9.3)% 0.3% (9.6)% OEM $220.3 $220.7 (0.2)% 0.4% (0.6)% TOTAL $2,537.2 $2,595.4 (2.2)% 0.2% (2.4)% Teleflex®#10Global Product Category Revenue Review As- Constant Dollars in Millions FY'20 FY'19 Reported Currency Currency Revenue Revenue Revenue Impact Growth Growth Vascular Access $657.7 $600.9 9.5% 0.1% 9.4% Interventional $382.4 $427.6 (10.6)% 0.1% (10.7)% Anesthesia $302.3 $338.4 (10.7)% 0.2% (10.9)% Surgical $317.2 $370.1 (14.3)% 0.2% (14.5)% Interventional Urology $290.0 $290.4 (0.1)% 0.1% (0.2)% OEM $220.3 $220.7 (0.2)% 0.4% (0.6)% Other¹ $367.3 $347.3 5.8% 0.5% 5.3% TOTAL $2,537.2 $2,595.4 (2.2)% 0.2% (2.4)% 10 1. Includes revenues generated from sales of the Company's respiratory and urology products (other than interventional urology products). Teleflex®#11Track Record of Revenue Growth, 2011-2020 (in millions) $2,550 $2,350 $2,150 6.1% Revenue CAGR1 2011-2020 $2,595 $2,537 $2,448 $2,146 $1,950 $1,868 $1,840 $1,810 $1,750 $1,696 $1,550 $1,493 $1,551 $1,350 $1,150 $950 $750 2011 11 1. Calculation based on GAAP reported revenue Note: Bar chart depicts as reported total annual Teleflex revenues 2012 2013 2014 2015 2016 2017 2018 2019 2020 Teleflex®#12Track Record of Adj. Gross and Operating Margin Expansion Adjusted Gross Margin Adjusted Operating Margin 51.5% 490 bp expansion 25.1% 25.7% 25.8% 520 bp expansion 58.1% 57.1% 24.1% 56.7% 55.8% 21.5% 20.0% 54.1% 52.7% 24.9% ך 2014 2015 2016 2017 2018 2019 2020 2014 2015 2016 2017 2018 2019 2020 12 Note: Figures represent adjusted gross and operating margin. See Appendices for reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures. Teleflex®#13• • • Core Strategic Building Blocks Teleflex is a Differentiated MedTech Asset Drive Constant Currency Revenue Growth Address major healthcare challenges Improve outcomes with less invasive, evidence-based procedures Accelerate long term revenue growth through scale M&A Deliver Non-Revenue Dependent Margin Expansion Execute restructuring and footprint realignment initiatives Take more of our business direct Leverage M&A across global infrastructure Remain a Serial Acquirer • Acquire high-growth, high-margin businesses with differentiated assets Focus on scale and late-stage technologies Improve process with each transaction Align Portfolio with Favorable Demographics Focus product suite on procedures that cannot be postponed Focus commercial efforts in geographies with improving demographics Continue to Attract Key Talent • Focus on culture Live our core values Keep people at the center of all we do 13 Teleflex®#14Teleflex 2021: Three-Year Growth Drivers ད Medium growth company with gross and operating margin expansion $$ Investing in key disease 2018 states Sustained cadence of new product launches Driving utilization in growth product categories Leveraging global infrastructure Executing on strategic M & A 14 High growth company with gross and operating margin expansion 2021 Teleflex®#1515 Investing in Key Disease States and Markets Vascular Catheter complications Interventional-Cardiac procedures - Surgical Minimally Invasive Procedures Emergency medicine Men's health Teleflex®#16Driving Utilization in Growth Product Categories Current Portfolio Interventional Urology Intraosseous Access Vascular Access Airway Management 16 Interventional Cardiology Chocolate® PTCA Balloon Catheter MANTAⓇ Vascular Closure Device The UroLift® System EZ-IO® Intraosseous Vascular Access System OnControl® Rüsch Polaris™ Fiber Powered Bone Access System PICCS Optic Single-Use Laryngoscope TurnpikeⓇ Catheters Guide Extension Select Pipeline Freeze Dried The UroLift® Plasma 2 System Weck AutoEndo HOL Large Clip Applier (AE10) *Teleflex Freeze Dried Plasma is not approved for sale or distribution. Wattson า M Teleflex®#1717 Executing Disciplined M&A Strategy Acquisition Criteria M&A Focus ⚫ Fits existing business units and call points 1 Scale • Provides superior clinical benefit 2 Tuck in • to existing alternatives Provides cost-benefit to the hospital Strong IP and patent protection ⚫ Long product life cycles 2011-2020 Cumulative Results • 74 deals closed 1 3 Dealer to direct 4 Late-stage technology . Transaction value of $4.1 billion 5 Reverse integration Teleflex®#1818 Track Record of Value-Creating Acquisitions M&A Focus Select Transactions 1 Scale Z-Medica 2020 NeoTract 2017 Vascular Solutions 2017 2 Tuck in QT Vascular 2018 Essential Medical 2018 Mini-Lap Technologies 2014 3 Dealer to direct VSI Distributors 2017-2018 Human Medics 2015 Mayo Healthcare 2014 4 Late-stage technology Airway Medix 2017 Atsina Surgical 2015 Nostix 2015 5 Reverse integration IWG HPC 2020 Truphatek 2015 Trintris Medical 2015 Teleflex®#1919 Key Investment Highlights Diversified, global medical technology company Well-positioned to take advantage of favorable industry dynamics Leading market positions with established global brands Diversified customer and supplier base Strong cash flow generation and proven history of deleveraging and margin expansion Experienced management team Teleflex®#2020 20 Spirit People Entrepreneurial Spil Make it Fun Building Trust THANK YOU Teleflex®#21Appendix A: Key Products Teleflex®Ⓡ#22NeoTract: A Compelling Growth Asset Significant Market Opportunity Exceptional Clinical Data Established Reimbursement Strong Commercial Infrastructure • UROLIFT® BPH Relief. In Sight..M Initial target market 8.5M U.S. BPH drug or drug drop out patients; $30B+ total addressable market 2 randomized controlled trials; 8 single arm studies • >28 peer-reviewed publications 5-year follow-up data published CPT1 code January 2015 The procedure is covered by Medicare and all national and major commercial plans, when medical criteria are met High quality commercial sales force & management team ⚫ Strong IP position and scalable manufacturing 242 22 Teleflex®#23UroLift® System: A Large Clinical Need and U.S. Market Opportunity 23 23 0.3 Surgery Drug drop out 1.5 UROLIFT® Drugs 7.0 BPH Relief. In Sight.. T Watchful waiting I 3.2 8.5 Million Men on drugs or drug drop out Uro Lift® System initial target market $30B + Opportunity 12 Million U.S. men treated for BPH1 # of men (millions) 1. U.S. Market Model 2019-2021 based on IQVIA (IMS Health) data Teleflex®#24UroLift® System: EMEA Size of Addressable Market EMEA represents a significant opportunity for BPH/LUTS treatment EMEA Addressable Market for Uro Lift¹ 30+ Mn Actively Managed BPH patients 24 24 1. Management estimates. Countries include Austria, Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, UK, Iran, Iraq, Israel, Jordan, UAE, Egypt, Kenya, Nigeria, South Africa, Uganda, and Zimbabwe, among others. Teleflex®#25UroLift® System: APAC Size of Addressable Market Asia Pacific represents a significant opportunity for BPH/LUTS treatment APAC Addressable Market for UroLift¹ 60+ Mn Actively Managed BPH patients 25 1. Management estimates. Countries include Australia, China, India, Indonesia, Japan, among others. Teleflex®#26UroLift® System: A Straightforward Procedure UROLIFT® BPH Relief. In Sight.IM 26 Apply Lidocaine jelly/oral sedative¹ Insert delivery system Gently push tissue aside Deploy customized implants Relieve obstruction Typically same day discharge 1. This does not account for the physician's preferred anesthesia protocol. UROLIFT Teleflex®#2727 UroLift® 2 System One implant per cartridge Nitinol Capsular Tab PET Suture Stainless Steel Urethral End Piece 8 mm • • E UroLift Implant design remains the same With the UroLift® 2 System, multiple cartridges per handle enable greater ease of use and reduce medical waste UROLIFT Teleflex®#2828 UroLift® ATCTM System UroLift® Advanced Tissue Control (ATCTM) is an optimized delivery device that offers enhanced tissue. control in cases with challenging anatomy such as obstructive median lobe (OML) or large lateral lobes. Wings at the tip allow the urologist to better grab and mobilize tissue into place prior to implant deployment. -15% of BPH patients present with OML.1 1. Doo, Urology 2009; 73: 232-236. Obstructive Middle Lobe was defined as high intravesical prostatic protrusion (IPP: grade 3, >10mm into bladder) and calculated as all patients with prostate contour Type 2 (2.5%)+73.3% of patients with contour Type 3 (19.1%) = 16.5%. Teleflex®#29UroLift: Reducing Tradeoffs Between Effectiveness and Risk Compared to Drugs Time to First Evidence of Statistically Significant Relief (Weeks) 1,2,3,4,5 12-24 5ARI Symptom Improvement Incidence of Sexual Dysfunction at 10-16 Months 5,6,7 Mean AUASI Reduction Ejaculatory Dysfunction Erectile Dysfunction 1-3 3.4 2 AB UROLIFT 5.6- 5 7 65 7.5 10.8 4% 0%- 10% 8% 3%- 5% 0% 5ARI AB UROLIFT 5ARI AB UROLIFT^5,7 5ARI AB DRUGS: 5ARI = 5 alpha reductase inhibitors AB alpha blockers Symptoms measured by AUASI (American Urological Association Symptom Index) ^ Sexual Dysfunction defined as new, onset sustained erectile or ejaculatory dysfunction. 0% UROLIFT™^5,7 29 1. Roehrborn, Rev Urol 2009; 11(suppl 1): S1-S8; 2. Rossi, Drug Des, Dev and Therap 2010; 4: 291-297 3. Pearson, Am Fam Phys 2014; 90 (11): 769-774; 4. Cindolo, Eur Urol 2015 Sep; 68(3): 418-25; 5. Roehrborn, J Urol 2013; 190: 2161-2167; 6. Sonksen, Eur Urol 2015; 68: 643-652; 7. AUA Guidelines 2003, 2010, 2014, which address a range of outcomes across alfuzosin, doxazosin, tamsulosin, and terazosin for ABS and only finasteride for 5ARIS Teleflex®#30ArrowⓇ EZ-IO® Intraosseous Vascular Access System Anesthesia and Emergency Medicine Top Market Trends ⚫ >137 million visits to the emergency room in the U.S. annually.1 • • • • • There are >500,000 adult occurrences of cardiac arrest yearly in the US with an estimated 10% survival rate.² Sepsis kills a patient in the U.S. every 2.3 Minutes. 3 As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.4 The EZ-IO® system enables rapid intravenous access in urgent emergent access situations that may include trauma or septic shock. Growth Strategy Go deep in high potential accounts Sustained leadership in professional, clinical and producttraining Methodical training on protocol for optimal outcomes Expand IP position in mechanical intraosseous access segment 30 1. CDC: National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables 2. Mozaffarian D, Benjamin EJ, Go AS, et al: on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322. DOI: 10.1161/CIR.0000000000000152. 3. Marik PE. Surviving sepsis: going beyond the guidelines. Ann Intensive Care. 2011. doi: 10.1186/2110-5820-1-17. 4. Kumar et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. June 2006;34(6)1589-96. Teleflex®#3131 0 • Anesthesia and Emergency Medicine Top Market Trends >137 million visits to the emergency room in the U.S. annually1 Minimal plasma availability in challenging environments (prehospital, remote/rural, battlefield settings), despite demand and opportunity to save many lives Traumatic injuries with hemorrhage require plasma transfusion to help stop life-threatening bleeding FDA and DoD launched joint program to expedite medical products intended to save lives of US military; including Freeze Dried Plasma Growth Strategy Partner with DOD through accelerated EUA/BLA regulatory pathway; conduct confirmatory efficacy study post licensure Establish battlefield (medic) and prehospital/remote settings (EMS paramedic) Expand to Trauma centers in hospital 1. CDC: National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables Freeze Dried Plasma is not approved for sale or distribution EZPLAZ Teleflex Freeze Dried Plasma Sterile Water for Injection USP 05/20 8 LOT J8E155 Rh NEGATIVE Teleflex®#32Freeze Dried Plasma Market Market Size Estimate Government ~$20M - $25M Civilian* ~$70M - $75M 32 32 Source: Management estimates *Does not include civilian trauma hospitals. Teleflex Freeze Dried Plasma is not approved for sale or distribution $ Total market size -$100M Teleflex®#3333 • ° ° 0 ° Coronary and Structural Heart Disease Top Market Trends Coronary artery disease is the most common type of heart disease in the US - cause of more than 370,000 deaths annually¹ Over 1 million percutaneous coronary interventions (PCI) are performed in the US every year² More than five million Americans are diagnosed with heart valve disease each year³ Approximately 8.5 million Americans suffer from peripheral arterial disease (PAD)4 Growth Strategy Expand new product pipeline Build brand awareness e Expand professional education programs • Deliver growth through M&A DO 1. CDC: https://www.cdc.gov/heartdisease/facts.htm 2. Mozaffarian D, et al. (2016). Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 133(4):e38-e360. 3. Alliance for Aging Research generated statistics, https://www.agingresearch.org/app/uploads/2018/06/Silver-Book-Valve-Disease-VOLUME-Final.pdf 4. CDC: https://www.cdc.gov/dhdsp/data_statistics/fact sheets/fs pad.htm - Roger VL, Go AS, Lloyd-Jones DM, et. al. Heart Disease and Stroke Statistics 2011 Update: A Report From the American Heart Association. Circulation 2011;123:e18-e209.. Teleflex®#34ArrowⓇ OnControl® Powered Bone Access System ~$160M Total Potential Addressable U.S. Market¹ . • • • Up to 55% faster procedure time to improve efficiency versus manual biopsy needles¹1 Fewer second-attempt procedures required versus manual biopsy needles 1,2 Consistently larger, high-quality core specimens versus manual biopsy needles 2,3,4,5 Increased user control and reduced physical requirements to obtain specimens 6,7 Demonstrated significantly less patient pain after the procedure than with use of manual biopsy needles 2,4 Results may vary from patient to patient. Rx only. The Arrow OnControl® Powered Bone Access System should only be used by clinicians familiar with the complications, limitations, indications, and contraindications of the indicated procedures. See Instructions For Use provided with the OnControl. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. 34 1. Cohen SC, Gore JM. Evaluation of a powered intraosseous device for bone marrow sampling. Anticanc Res 2008;28:3843-8. Research sponsored by Teleflex Incorporated. 2. Swords RT, Anguita J, Higgins RA, et al. A prospective randomized study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. J Clin Pathol 2011;64(9):809-13. doi:10.1136/jclinpath-2011-200047. Research sponsored by Teleflex Incorporated. 3. Berenson JR, Yellin O, Blumenstein B, et al. Using a powered bone marrow biopsy system results in shorter procedures, causes less residual pain to adult patients, and yields larger specimens. Diagn Pathol. 2011;6:23. Research sponsored by Teleflex Incorporated. 2. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3:e8.t. Research sponsored by Teleflex Incorporated. Incorporated. Phibeck TE and Montez OF are employees of Teleflex Incorporated. 4. Reed LJ, Raghupathy R, Strakhan M, et al. The OnControl bone marrow biopsy technique is superior to the standard manual technique for hematologists-in-training: a prospective, randomized comparison. Hematology Reports 2011;3(e21). doi:10.4081/hr.2011.e21. Research sponsored by Teleflex Incorporated. 5. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a battery-powered drill system: preliminary results. AJR Am J Roentgenol 2013;201(5):1093-5. doi: 10.2214/AJR.12.10521. 6. Symington KE, Martinez F, Cohen SC, Miller LJ, Philbeck, TE. CT-guided biopsy produces high quality specimens for diagnosis: a retrospective analysis of 64 consecutive cases using a powered biopsy device at a community-based hospital. Blood 2013; 122:5381. Teleflex®#3535 ArrowⓇ AC3 OptimusⓇ Intra-Aortic Balloon Pump Simply outstanding performance, support, and efficiency in an IABP For patients requiring mechanical cardiac support, the performance of the IABP can mean all the difference. With the onset of an elevated heart rate or arrhythmia, the patient's survival can suddenly depend on the ability of the IABP to keep pace with the situation. The AC3 OptimusⓇ Intra-Aortic Balloon Pump provides intra-beat inflation timing accuracy across a wide range of patient conditions — including those with severe arrhythmias. 1,2 1. Donelli A, Jansen JRC, Hoeksel B, et. al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhytmic human aortic pressure signals. J Clin Monit. 2002;17(3-4):1 185. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor. Co-authors J. Bovelander and R. Hanania are current or former employees of the study sponsor. 2. Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic balloon pump timing using an intra beat dicrotic notch prediction algorithm. Ann Thorac Surg. 2005;79(3):1017- 1022. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor. Co-authors J. Bovelander, R. Hanania, and P. Hanlon are current or former employees of the study sponsor. 111 Teleflex®#36MantaⓇ Vascular Closure Device A new era of simplicity and confidence in large bore closure The MANTAⓇ Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 Available in 14 Fr. and 18 Fr., a single MANTA Device effectively closes femoral arterial access sites following the use of large bore sheaths ranging from 12 Fr. to 25 Fr. O.D. 2b Simple deployment Addresses the challenges of femoral arterial access site closure with a single easy-to-use device.2b Rapid hemostasis Reduces time to hemostasis without pre-closure, utilizing the coagulation-inducing properties of collagen for rapid hemostasis to promote vessel healing. 2c,3-5 Reliable closure Delivers reproducible results and helps inspire confidence in achieving successful closure.2d 36 1. Data on file at Teleflex. 2. Data on file at Teleflex. The SAFE MANTA IDE Clinical Trial. 2a. Major Complications defined as composite of: i) vascular injury requiring surgical repair/stent-graft; ii) bleeding requiring transfusion; iii) lower extremity ischemia requiring surgical repair/additional percutaneous intervention; iv) nerve injury (permanent or requiring surgical repair); and v) infection requiring IV antibiotics and/or extended hospitalization. 2b. A single MANTATM Device was deployed in 99.6% of subjects in the IDE trial. 2c. The MANTAT Device demonstrated a time to hemostasis (TTH) of 24 seconds median time (65 seconds mean time) from deployment to hemostasis, which is lower than published rates for Perclose ProGlide® where Perclose ProGlide® demonstrated a TTH of 9.8 +/- d. 17 minutes (588 +/- 1,020 seconds). 3 97.7% Technical Success, defined as percutaneous vascular closure obtained with the MANTATM Device without the use of unplanned endovascular or surgical intervention. Study sponsored by Teleflex Incorporated or its affiliates. 3. Nelson PR, et al. A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial). J Vasc Surg. 2014 May;59(5): 1081-1193. 4. Farndale RW, et al. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004 Apr;2(4):564-573. 5. Nuyttens BP, et al. Platelet adhesion to collagen. Thromb Res. 2011;127(2): S26-S29. Teleflex® MANTA MANTA#3737 Guideliner® V3 Catheter Guide extension catheter with half-pipe technology The GuideLiner® Catheter revolutionized the concept of guide extension, creating new possibilities in interventional cardiology. Now in its third generation, the GuideLinerⓇ V3 Catheter continues to build on a history of innovation and performance one that's been demonstrated with more than half a million catheters in cath labs around the world.1 Half-pipe technology The half-pipe channel is designed to minimize device/collar interaction by directing and aligning devices through the collar transition, facilitating smooth device entry and seamless delivery. COLLAR TRANSITION HALF-PIPE CHANNEL V3 HALF-PIPE TECHNOLOGY 1. Data on file. Teleflex®#3838 TurnpikeⓇ Catheters Turnpike Spiral Catheter Distal nylon coil provides rotational assistance for enhanced trackability Turnpike Gold Catheter Gold-plated, threaded metallic tip for enhanced advancement TurnpikeⓇ LP Catheter Low-profile version with greater tip and distal shaft flexibility for advancement through extreme tortuosity Teleflex®#3939 TrapLiner® Catheter Guide Extension Plus Wire Trapping • Balloon inflates to maintain guidewire position • Rapid exchange guide extension for backup support and deep-seating Gold radiopaque marker identifies trapping balloon location Balloon inflates via a hypotube push rod to trap, the guidewire against the interior wall of the guide catheter GuidelinerⓇ Catheter design but with shortened rapid exchange guide extension segment and hydrophilic coating Teleflex®#40A Less Invasive Surgical Approach Top Market Trends 3.5 million laparoscopic procedures performed in the US Annually1 Patient and clinician demand for decreased trauma and enhanced safety Patient satisfaction influence on reimbursement WeckⓇ EFX Shield® Port Closure Device Improved Safety WECK ° Growth Strategy Broad awareness through market development activities generate demand for targeted elective procedures Deepen surgical congress society relationships Build clinical evidence with key teaching institutions Continued investment in refining and broadening product portfolio 40 1. Idata research: United States Market Report Suite for Laparoscopic Devices, 2017 Percutaneous Laparoscopic Instruments Less Trauma Heak Pesos FEA Curved Spatal P Conta Straight Spatule Pro Mrian Teleflex®#4141 WeckⓇ Hem-o-lokⓇ Polymer Ligation Systems Product Description WeckⓇ Hem-o-lokⓇ polymer ligation clips are designed for cool ligation, lasting security and fast, efficient delivery - secure from the cartridge to the applier and on the vessel. The WeckⓇ Hem-o-lok® polymer ligation system unique design offers: • A flexible hinge that keeps the clip firmly seated in the applier jaws ⚫ Tactile feedback that confirms jaw seating and secure vessel placement • ⚫ Distal locking clip to signal closure Teleflex®#42• Catheter Complications: Antimicrobial Technology Top Market Trends Increasing awareness of vascular-related complications with PICCS and midlines Protected Catheters 0 Pressures on healthcare funding linked to patient outcomes • Increasing awareness of infection and thrombosis driving penalties and therapy costs 6 MOLINE-PROXIMAL • 42 0 • Growth Strategy Portfolio enhancement around reducing vascular-related complications that equally benefit patients and clinicians Data driven, health economic selling and consultative approaches Leverage tip placement navigation technology in PICCs and CVCS Drive standardization through our coating and kitting strategies Investment and launch of several clinical education and professional education programs Catheter Navigation VPS Rhythm Teleflex®#4343 ArrowⓇ ErgoPack Complete System ARROW Product Description The latest addition to the Arrow® Brand represents an evolution in progressive design, featuring clinician- inspired enhancements. We observed thousands of hours of procedures to create an intuitive configuration that allows for efficient procedural workflow and compliance with clinical best practices. Key features include an intuitive layout of components, smart labeling, a kink-resistant nitinol wire, transducer cover, option for innovative dressing technologies, and Arrow® GlideWheel TM Advancer. Teleflex®#44Arrowg+ard Blue Advance ® PICC No CT 44 • Patients with known hypersensitivity to chlorhexidine Product Description Pressure-injectable Arrowg+ard Blue AdvanceⓇ PICCs are the world's first PICCs in the intravascular catheter marketplace with both broad-spectrum antimicrobial and antithrombogenic protection. Extra- and intraluminal protection helps reduce the colonization of some pathogens responsible for causing central line-associated bloodstream infections (CLABSIS). 1,2 Chlorhexidine helps to reduce thrombus accumulation on the catheter surfaces.1 The Arrowg+ard Blue AdvanceⓇ PICC is available in a complete portfolio of single-, double- and triple-lumen formats and related kits. 1. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus. No correlation between these testing methods and clinical outcome has currently been ascertained. 2. In vitro data on file 2010. No correlation between these testing methods and clinical outcome has currently been ascertained. Arrowg+ard Blue Advance Catheters are contraindicated in the following areas: •In presence of device related infections •In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. Teleflex®#45Appendix B: GAAP to Non-GAAP Reconciliations Teleflex®Ⓡ#46Note on Non-GAAP Financial Measures The presentation to which these appendices are attached, and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: • • • Constant currency revenue growth. This measure excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items, (ii) acquisition, integration and divestiture related items and (iii) other items identified in note (C) to the reconciliation tables appearing in Appendix B. Adjusted operating profit and margin. These measures exclude, depending on the period presented, (i) the impact of restructuring, restructuring related and impairment items; (ii) acquisitions, integration and divestiture related items; (iii) other items identified in note (C) to the reconciliation tables appearing in Appendix C. Adjusted diluted earnings per share. This measure excludes, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) other items identified in note (C) to each of the reconciliation tables appearing in Appendices D and E; (iv) amortization of the debt discount on the Company's previously outstanding convertible notes; (v) intangible amortization expense; (vi) loss on extinguishment of debt; and (vii) tax adjustments identified in note (G) to the reconciliation tables appearing in Appendices D and E. In addition, the calculation of diluted shares within adjusted earnings per share for the 2017 periods gives effect to the anti-dilutive impact of the Company's previously outstanding convertible note hedge agreements, which reduced the potential economic dilution that otherwise would have occurred upon conversion of the Company's senior subordinated convertible notes (under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares). 60 46 Teleflex®#47Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring, restructuring related and impairment items. Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, as a result of periodic impairment testing or due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items. Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of the divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Other items. These are discrete items that occur sporadically and can affect period-to-period comparisons. Amortization of debt discount on convertible notes. When we sold $400 million principal amount of our 3.875% convertible notes (the "convertible notes") in 2010, we allocated the proceeds between the liability and equity components of the debt, in accordance with GAAP. As a result, the $83.7 million difference between the proceeds of the sale of the convertible notes and the liability component of the debt constituted a debt discount that was to be amortized to interest expense over the approximately seven-year term of the convertible notes, which significantly increased the amount we recorded as interest expense attributable to the convertible notes. The amount of the amortization of the debt discount was reduced as a result of our repurchases of convertible notes in 2016 and 2017 and redemptions of the convertible notes by holders of the notes, although we continued to amortize the remaining portion of the debt discount to interest expense until August 2017, when all remaining convertible notes were either converted or matured. Intangible amortization expense. Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. Loss on extinguishment of debt. In connection with debt refinancings, debt repayments, repurchases of convertible notes and redemptions of convertible notes, outstanding indebtedness is extinguished. These events, which have occurred from time to time on an irregular basis, have resulted in losses reflecting, among other things, unamortized debt issuance costs, as well as debt prepayment fees and premiums (including conversion premiums resulting from conversion of convertible securities). Tax adjustments. These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law changes affecting our deferred tax liability. Adjusted diluted shares. Adjusted diluted shares are calculated by giving effect to the anti-dilutive impact of the Company's convertible note hedge agreements, which reduced the potential economic dilution that otherwise would have occurred upon conversion of the Company's convertible notes. Under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in the weighted average number of diluted shares. 47 Teleflex®#4848 188 Appendix A - Reconciliation of Adjusted Gross Profit and Margin Dollars in Thousands Gross profit as-reported Gross margin as-reported Restructuring, restructuring related and impairment items (A) Acquisition, integration and divestiture related items (B) Other items (C) Intangible Amortization (D) Adjusted gross profit Adjusted gross margin Revenue as-reported Please see slide 52 for full tickmarks Twelve Months Ended December 31, 2014 December 31, 2015 December 31, 2016 December 31, 2017 December 31, 2018 December 31, 2019 December 31, 2020 $ 942,428 $ 51.2% 4,886 944,403 $ 52.2% 9,449 996,200 $ 1,171,802 $ 1,302,816 $ 1,409,005 $ 1,324,874 53.3% 54.6% 53.2% 54.3% 52.2% 14,559 12,730 13,441 15,874 25,872 10,795 1,058 97 3,602 1,347 (1,347) 81,626 82,607 84,432 $ 947,314 $ 51.5% 953,852 $ 52.7% 1,010,759 $ 54.1% 1,195,327 $ 1,397,594 $ 1,507,583 $ 55.7% 57.1% 58.1% 1,438,780 56.7% $ 1,839,832 $ 1,808,690 $ 1,868,027 $ 2,146,303 $ 2,448,383 $ 2,595,362 $ 2,537,156 Teleflex®#49Appendix B - Reconciliation of Adjusted Operating Profit and Margin Dollars in Thousands Twelve Months Ended December 31, 2014 December 31, 2015 December 31, 2016 December 31, 2017 December 31, 2018 December 31, 2019 December 31, 2020 Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 284,862 $ 315,891 $ 319,453 $ 372,279 $ 321,704 $ 427,254 $ 423,068 Income from continuing operations before interest, loss on extinguishment of debt and taxes margin 15.5% 17.5% 17.1% 17.3% 13.1% 16.5% 16.7% Restructuring, restructuring related and impairment items (A) 28,749 17,314 74,559 29,371 93,957 38,490 65,226 Acquisition, integration and divestiture related items (B) Other items (C) (7,549) (3,498) (7,399) 38,802 60,321 49,299 (26,805) 600 (3,040) 572 Intangible amortization expense (D) 60,926 62,380 63,491 (551) 98,766 2,907 1,814 149,486 MDR costs (E) 149,974 3,194 1,078 158,685 11,267 Adjusted income from continuing operations before interest, loss on extinguishment of debt and taxes 367,588 $ 389,047 $ 450,676 $ 538,667 $ 628,375 $ 670,025 $ 632,519 Adjusted income from continuing operations before interest, loss on extinguishment of debt and taxes margin 20.0% 21.5% 24.1% 25.1% 25.7% 25.8% 24.9% Revenue as-reported $ 1,839,832 $ 1,809,690 $ 1,868,027 $ 2,146,303 $ 2,448,383 $ 2,595,362 $ 2,537,156 49 Please see slide 52 for full tickmarks Teleflex®#50Appendix C Reconciliation of Adjusted Earnings per Share Twelve Months Ended December 31, 2014 December 31, 2015 December 31, 2016 December 31, 2017 December 31, 2018 December 31, 2019 December 31, 2020 2014-20 CAGR 4.10 $ 4.91 $ 4.98 $ 3.33 $4.20 $9.81 $7.10 9.6% GAAP diluted earnings per share available to common shareholders $ GAAP year-over-year growth Restructuring, restructuring related and impairment items (A) Acquisition, integration and divestiture related items (B) Other items (C) MDR costs (D) Amortization of debt discount on convertible notes Intangible amortization expense Loss on extinguishment of debt Tax adjustments Shares due to Teleflex under note hedge 19.8% 1.4% -33.1% 26.1% 133.6% -27.6% 0.45 0.23 1.03 0.44 $1.76 0.71 1.32 (0.17) (0.09) (0.11) 0.79 $1.27 1.11 (0.59) 0.01 (0.04) 0.01 0.01 $0.06 0.17 0.02 0.07 0.24 0.17 0.17 0.10 0.01 0.94 0.95 0.99 1.52 $2.63 2.59 2.84 0.14 0.26 0.08 (0.09) (0.39) (0.23) 2.17 ($0.01) (3.31) (0.25) 0.33 0.44 0.31 0.05 Adjusted diluted earnings per share available to common shareholders $ 5.74 $ 6.33 $ 7.34 $ 8.40 $ 9.90 S 11.15 $10.67 10.9% Adjusted year-over-year growth 50 50 10.3% 16.0% 14.4% 17.9% 12.6% -4.3% Teleflex®#51Appendix D - Tickmarks (A) Restructuring, restructuring related and impairment items -In 2014 and 2015, the majority of these charges were related to facility consolidations. In 2016, these charges include; (i) charges related to facility consolidations, (ii) a pre-tax, non-cash $41.0 million impairment charge and a $14.9 million reduction in related deferred tax liabilities in connection with discontinuation of an in-process research and development project; (iii) $2.4 million in pre-tax, non-cash impairment charges related to two properties, one of which was classified as an asset held for sale and (iv) a $0.7 million reduction in related deferred tax liabilities. For the twelve months ended December 31, 2017 and December 31, 2018, pre-tax restructuring related charges were $14.6 million and $14.7 million, respectively. For the twelve months ended December 31, 2017 and December 31, 2018, pre-tax impairment charges were $0.0 million and $19.1 million, respectively. For the twelve months ended December 31, 2019 pre-tax restructuring charges were $15.2 million, pre-tax restructuring related charges were $16.3 million, and pre-tax impairment charges were $7.0 million. For the twelve months ended December 31, 2020, pre-tax restructuring charges were $17.1 million, pre-tax restructuring related charges were $26.7 million, and pre-tax impairment charges were $21.4 million. (B) Acquisition, integration and divestiture related items - In 2014 and 2015, the majority of these charges were related to contingent consideration liabilities, somewhat offset by acquisition costs. In 2016, the majority of these charges were related to reversals related to contingent consideration liabilities, including $8.3 million related to the discontinuation of an in-process research and development project, and the gain on a sale of assets, somewhat offset by acquisition costs. For the twelve months ended December 31, 2017, these charges were primarily related to our acquisitions of Vascular Solutions and NeoTract, as well as contingent consideration liabilities. For the twelve months ended December 31, 2018, these charges were primarily related to contingent consideration liabilities and our acquisition of NeoTract. For the twelve months ended December 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of Essential Medical, Inc., partially offset by the gain on sale of a business and two assets. For the year ended December 31, 2020, these items primarily related to the reversal of contingent consideration liabilities, partially offset by charges primarily related to our acquisitions of IWG High Performance Conductors, Inc. and Z-Medica, LLC. and the reversal of previously recognized income related to a distributor conversion in Japan. (C) Other items In 2015, the majority of these charges were related to the medical device excise tax and a litigation verdict against the Company with respect to a non-operating joint venture. In 2016, the majority of these charges were related to relabeling costs and costs associated with a facility that was exited. For the twelve months ended December 31, 2017, other items included both gains and losses associated with litigation settlements, the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, the reversal of previously recognized income due to our distributor to direct sales conversion in China, and relabeling costs. For the twelve months ended December 31, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, losses associated with settlement of ligation relating to an intellectual property matter, expenses associated with a franchise tax audit, and relabeling costs. Other items for the twelve months ended December 31, 2018 included a charge we incurred, as a result of the Tax Cuts and Jobs Act ("TCJA"), on our consolidated operations. During the second quarter of 2018, we identified provisions of the TCJA that could have adverse consequences due to our organizational structure. We implemented certain changes in the organizational structure (with, pursuant to tax law, retroactive impact back to 2017), as a result of which, we incurred a $1.9 million net worth tax in a foreign jurisdiction with respect to the 2017 tax year. Because the decision to make the change resulting in the net worth tax occurred in the second quarter of 2018, and as permitted under GAAP, we recorded the net worth tax charge in 2018, and the adjustment eliminating the charge is included in the table for the year ended December 31, 2018. For the twelve months ended December 31, 2019, other items included debt modification and extinguishment expenses, expenses associated with a franchise tax audit, and product relabeling costs, partially offset by a credit associated with an insurance settlement. For the year ended December 31, 2020, other items included expenses associated with a franchise tax audit and prior year tax matters. (D) Intangible Amortization - For the twelve months ended December 31,2018 and December 31, 2019, we reclassified $81.6 million and $82.6 million respectively, from selling, general and administrative expenses to cost of goods sold. For the year ended December 31, 2020 intangible asset amortization expense of $84.4 million is included in cost of goods sold. (E) MDR For the twelve months ended December 31, 2020 and December 31, 2019, these costs were associated with our efforts to comply with the European Medical Device Regulation. The costs associated with the European Medical Device Regulation initiative include $0.3 million that were a component of the "Other items" line item in the reconciliation table for the three months ended March 31, 2019 included in our first quarter 2019 earnings release. 51 Teleflex®